Related references
Note: Only part of the references are listed.Impaired insulin secretion predicting unstable glycemic variability and time below range in type 2 diabetes patients regardless of glycated hemoglobin or diabetes treatment
Aika Miya et al.
JOURNAL OF DIABETES INVESTIGATION (2021)
Favourable effect of the sodium-glucose co-transporter-2 inhibitor canagliflozin plus the dipeptidyl peptidase-4 inhibitor teneligliptin in combination on glycaemic fluctuation: An open-label, prospective, randomized, parallel-group comparison trial (the CALMER study)
Kyu Yong Cho et al.
DIABETES OBESITY & METABOLISM (2020)
Canagliflozin Increases Calorie Intake in Type 2 Diabetes Without Changing the Energy Ratio of the Three Macronutrients: CANA-K Study
Ikuro Matsuba et al.
DIABETES TECHNOLOGY & THERAPEUTICS (2020)
Time in range: a new parameter to evaluate blood glucose control in patients with diabetes
Monica Andrade Lima Gabbay et al.
DIABETOLOGY & METABOLIC SYNDROME (2020)
Concurrent Use of Teneligliptin and Canagliflozin Improves Glycemic Control with Beneficial Effects on Plasma Glucagon and Glucagon-Like Peptide-1: A Single-Arm Study
Tomoho Noda et al.
DIABETES THERAPY (2019)
Sodium-glucose cotransporter 2 inhibitor, tofogliflozin, shows better improvements of blood glucose and insulin secretion in patients with high insulin levels at baseline
Kazuyuki Tobe et al.
JOURNAL OF DIABETES INVESTIGATION (2018)
Metrics for glycaemic control - from HbA1c to continuous glucose monitoring
Boris P. Kovatchev
NATURE REVIEWS ENDOCRINOLOGY (2017)
A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin
Hiroshi Nomoto et al.
DIABETOLOGY & METABOLIC SYNDROME (2017)
Efficacy and safety of canagliflozin as add-on therapy to teneligliptin in Japanese patients with type 2 diabetes mellitus: Results of a 24-week, randomized, double-blind, placebo-controlled trial
Takashi Kadowaki et al.
DIABETES OBESITY & METABOLISM (2017)
Effects of luseogliflozin, a sodium-glucose co-transporter 2 inhibitor, on 24-h glucose variability assessed by continuous glucose monitoring in Japanese patients with type 2 diabetes mellitus: a randomized, double-blind, placebo-controlled, crossover study
R. Nishimura et al.
DIABETES OBESITY & METABOLISM (2015)
Ameliorated pancreatic β cell dysfunction in type 2 diabetic patients treated with a sodium-glucose cotransporter 2 inhibitor ipragliflozin
Mitsuyoshi Takahara et al.
ENDOCRINE JOURNAL (2015)
Evaluation of pharmacokinetic and pharmacodynamic interactions of canagliflozin and teneligliptin in Japanese healthy male volunteers
Shuji Kinoshita et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2015)
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Aurora Merovci et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Hypo- and Hyperglycemia in Relation to the Mean, Standard Deviation, Coefficient of Variation, and Nature of the Glucose Distribution
David Rodbard
DIABETES TECHNOLOGY & THERAPEUTICS (2012)
Share Paper
